N-Glycoprofiling of SLC35A2-CDG: Patient with a Novel Hemizygous Variant

Congenital disorders of glycosylation (CDG) are a group of rare inherited metabolic disorders caused by a defect in the process of protein glycosylation. In this work, we present a comprehensive glycoprofile analysis of a male patient with a novel missense variant in the SLC35A2 gene, coding a galactose transporter that translocates UDP-galactose from the cytosol to the lumen of the endoplasmic reticulum and Golgi apparatus. Isoelectric focusing of serum transferrin, which resulted in a CDG type II pattern, was followed by structural analysis of transferrin and serum N-glycans, as well as the analysis of apolipoprotein CIII O-glycans by mass spectrometry. An abnormal serum N-glycoprofile with significantly increased levels of agalactosylated (Hex3HexNAc4-5 and Hex3HexNAc5Fuc1) and monogalactosylated (Hex4HexNAc4 ± NeuAc1) N-glycans was observed. Additionally, whole exome sequencing and Sanger sequencing revealed de novo hemizygous c.461T > C (p.Leu154Pro) mutation in the SLC35A2 gene. Based on the combination of biochemical, analytical, and genomic approaches, the set of distinctive N-glycan biomarkers was characterized. Potentially, the set of identified aberrant N-glycans can be specific for other variants causing SLC35A2-CDG and can distinguish this disorder from the other CDGs or other defects in the galactose metabolism.

[1]  D. Hassabis,et al.  AlphaFold Protein Structure Database: massively expanding the structural coverage of protein-sequence space with high-accuracy models , 2021, Nucleic Acids Res..

[2]  A. Hlavatá,et al.  A novel homozygous mutation in the human ALG12 gene results in an aberrant profile of oligomannose N‐glycans in patient's serum , 2021, American journal of medical genetics. Part A.

[3]  Oriol Vinyals,et al.  Highly accurate protein structure prediction with AlphaFold , 2021, Nature.

[4]  Jian-She Wang,et al.  Four New Cases of SLC35A2-CDG With Novel Mutations and Clinical Features , 2021, Frontiers in Genetics.

[5]  G. Matthijs,et al.  SLC35A2-CDG: Novel variant and review , 2021, Molecular genetics and metabolism reports.

[6]  A. Jezela-Stanek,et al.  Congenital Disorders of Glycosylation from a Neurological Perspective , 2021, Brain sciences.

[7]  OUP accepted manuscript , 2021, Nucleic Acids Research.

[8]  O. Birk,et al.  B4GALT1‐congenital disorders of glycosylation: Expansion of the phenotypic and molecular spectrum and review of the literature , 2020, Clinical genetics.

[9]  F. Scaglia,et al.  Clinical and biochemical improvement with galactose supplementation in SLC35A2-CDG , 2020, Genetics in Medicine.

[10]  J. Rosenfeld,et al.  SLC35A2‐CDG: Functional characterization, expanded molecular, clinical, and biochemical phenotypes of 30 unreported Individuals , 2019, Human mutation.

[11]  B. D. de Vries,et al.  Clinical, neuroradiological, and biochemical features of SLC35A2‐CDG patients , 2019, Journal of inherited metabolic disease.

[12]  Gregory M. Cooper,et al.  CADD: predicting the deleteriousness of variants throughout the human genome , 2018, Nucleic Acids Res..

[13]  Christina Lam,et al.  Congenital disorders of glycosylation. , 2018, Annals of translational medicine.

[14]  E. I. Pierpont,et al.  Mosaicism of the UDP-Galactose transporter SLC35A2 in a female causing a congenital disorder of glycosylation: a case report , 2018, BMC medical genetics.

[15]  J. Zeman,et al.  Aberrant apolipoprotein C-III glycosylation in glycogen storage disease type III and IX. , 2018, Metabolism: clinical and experimental.

[16]  Chunlei Liu,et al.  ClinVar: improving access to variant interpretations and supporting evidence , 2017, Nucleic Acids Res..

[17]  G. Matthijs,et al.  Congenital disorders of glycosylation (CDG): Quo vadis? , 2017, European journal of medical genetics.

[18]  Mauricio O. Carneiro,et al.  Scaling accurate genetic variant discovery to tens of thousands of samples , 2017, bioRxiv.

[19]  R. Durbin,et al.  Evaluation of GRCh38 and de novo haploid genome assemblies demonstrates the enduring quality of the reference assembly , 2016, bioRxiv.

[20]  R. Wevers,et al.  High-resolution mass spectrometry glycoprofiling of intact transferrin for diagnosis and subtype identification in the congenital disorders of glycosylation. , 2015, Translational research : the journal of laboratory and clinical medicine.

[21]  Y. Wada,et al.  A new case of UDP-galactose transporter deficiency (SLC35A2-CDG): molecular basis, clinical phenotype, and therapeutic approach , 2015, Journal of Inherited Metabolic Disease.

[22]  Björn Usadel,et al.  Trimmomatic: a flexible trimmer for Illumina sequence data , 2014, Bioinform..

[23]  Y. Wada,et al.  De Novo Mutations in SLC35A2 Encoding a UDP‐Galactose Transporter Cause Early‐Onset Epileptic Encephalopathy , 2013, Human mutation.

[24]  B. Xia,et al.  Serum N-glycan and O-glycan analysis by mass spectrometry for diagnosis of congenital disorders of glycosylation. , 2013, Analytical biochemistry.

[25]  B. Xia,et al.  N- and O-linked glycosylation of total plasma glycoproteins in galactosemia. , 2012, Molecular genetics and metabolism.

[26]  H. Freeze,et al.  TMEM165 deficiency causes a congenital disorder of glycosylation. , 2012, American journal of human genetics.

[27]  Pablo Cingolani,et al.  Using Drosophila melanogaster as a Model for Genotoxic Chemical Mutational Studies with a New Program, SnpSift , 2012, Front. Gene..

[28]  R. Wevers,et al.  Plasma N-glycan profiling by mass spectrometry for congenital disorders of glycosylation type II. , 2011, Clinical chemistry.

[29]  Helga Thorvaldsdóttir,et al.  Integrative Genomics Viewer , 2011, Nature Biotechnology.

[30]  Richard Durbin,et al.  Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .

[31]  Alessio Ceroni,et al.  GlycoWorkbench: a tool for the computer-assisted annotation of mass spectra of glycans. , 2008, Journal of proteome research.

[32]  K. Henrick,et al.  Inference of macromolecular assemblies from crystalline state. , 2007, Journal of molecular biology.

[33]  Cathy H. Wu,et al.  UniProt: the Universal Protein knowledgebase , 2004, Nucleic Acids Res..

[34]  Elizabeth M. Smigielski,et al.  dbSNP: the NCBI database of genetic variation , 2001, Nucleic Acids Res..

[35]  G. Matthijs,et al.  Congenital disorders of glycosylation. , 2000, Trends in biochemical sciences.

[36]  G. von Heijne,et al.  Proline-induced disruption of a transmembrane alpha-helix in its natural environment. , 1998, Journal of molecular biology.

[37]  C. Deber,et al.  Alpha-helical, but not beta-sheet, propensity of proline is determined by peptide environment. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[38]  T. Arndt,et al.  Effect of separation conditions on automated isoelectric focusing of carbohydrate-deficient transferrin and other human isotransferrins using the PhastSystem. , 1995, Analytical biochemistry.

[39]  J. Thompson,et al.  CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. , 1994, Nucleic acids research.

[40]  H. G. van Eijk,et al.  Microheterogeneity of human serum transferrin: A biological phenomenon studied by isoelectric focusing in immobilized pH gradients , 1988, Electrophoresis.